Urogen Pharma Ltd
NASDAQ:URGN
Urogen Pharma Ltd
NASDAQ:URGN
Price:
14.4 USD
4.2%
Market Closed
Updated:
May 2, 2024
Urogen Pharma Ltd
Cash from Operating Activities
|
Urogen Pharma Ltd
Cash from Operating Activities Peer Comparison
Comparables:
CLGN
KMDA
B
BLRX
ENTX
B
BONS
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash from Operating Activities
-$76.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Cash from Operating Activities
-$2.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash from Operating Activities
$4.3m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Cash from Operating Activities
-$22.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash from Operating Activities
-$7.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Cash from Operating Activities
-₪26.5m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-12%
|
See Also
What is Urogen Pharma Ltd's Cash from Operating Activities?
Cash from Operating Activities
-76.4m
USD
-76.4m
USD
Based on the financial report for Dec 31, 2023, Urogen Pharma Ltd's Cash from Operating Activities amounts to -76.4m USD.
What is Urogen Pharma Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-15%
-15%
Over the last year, the Cash from Operating Activities growth was 13%. The average annual Cash from Operating Activities growth rates for Urogen Pharma Ltd have been 10% over the past three years , -15% over the past five years .
You don't have any saved screeners yet
